Indoco Remedies has announced that its Goa Plant-I has received European Union Good Manufacturing Practice (EU GMP) certification from the Malta Medicines Authority.
The certification follows the successful completion of an inspection at the company's solid oral dosage manufacturing facility in Goa.
The Malta Medicines Authority inspected Indoco Remedies' Goa Plant-I from November 19 to November 24, 2025.
Following the inspection, the regulatory authority granted EU GMP certification, confirming that the facility complies with the Good Manufacturing Practice requirements referred to in the European Commission Directive.
The EU GMP certification enables the Goa manufacturing facility to continue supplying pharmaceutical products that require compliance with European Good Manufacturing Practice standards.
The certification also reinforces the company's quality systems and regulatory compliance across international markets.
Indoco Remedies operates 10 manufacturing facilities, including 6 finished dosage formulation (FDF) plants and four active pharmaceutical ingredient (API) facilities.
The company said its manufacturing facilities have received approvals from several global regulatory authorities, including the USFDA and the UK's MHRA.
Read More: Indoco Remedies Share Price Gains Over 13% on Q4 FY26 Earnings Results: Total Income up 21.2% YoY!
As of 29 June 2026, at 1:48 PM, Indoco Remedies share price was trading at ₹237.13 per share, reflecting a surge of 2.39% from the previous trading session.
Indoco Remedies has received EU GMP certification for its Goa Plant-I from the Malta Medicines Authority after successfully completing a regulatory inspection. The certification strengthens the company's international regulatory compliance and supports its global pharmaceutical manufacturing operations.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jun 29, 2026, 2:51 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
